RIPK3 and idiopathic pulmonary fibrosis: Our findings extend RIPK3 biology beyond its classical role in cell death, highlighting RIPK3 as a key metabolic regulator of the fibrotic niche and suggesting that targeting this immunometabolic axis represents a promising therapeutic strategy for IPF.